Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington’s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.

Biotechnology

Triplet Therapeutics

Nessan Bermingham

Jia Tay

W. George Lai

Peter Bialek

Alan J. Buckler

Eric Sullivan

Deborah Gouveia

Jeff Cerio

Irina Antonijevic

Amar Ghodasara

David Morrissey

Amy Lurier

Satya Kuchimanchi

Pei Ge

Brian Bettencourt

Eva Asp

The Research and Development team at Triplet Therapeutics focuses on advancing innovative therapeutic solutions for repeat expansion disorders by leveraging genetic insights and their proprietary thRED Engine. This multidisciplinary team, comprising experts in molecular biology, pharmacology, and translational sciences, collaborates to design, develop, and refine oligonucleotide-based treatments that target the DNA Damage Response pathway, aiming to deliver effective therapies for multiple REDs.

Research and Development

Leadership Team

Corporate Functions

Research and Development

About

Team members

Other teams at Triplet Therapeutics

Leadership Team

Corporate Functions